Literature DB >> 9625422

CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles.

N M Almasri1, J A Iturraspe, R C Braylan.   

Abstract

BACKGROUND AND OBJECTIVES: CD10 is a proteolytic enzyme expressed on the surface of germinal center cells and lymphomas derived from these cells. There is a well-known association between CD10 expression and lymphomas of follicular center cell origin. However, the reported frequency of CD10 positivity in follicular lymphomas is widely variable, and no studies have addressed the importance of assessing the intensity of CD10 expression in the diagnosis of these tumors. In this study, we utilized flow cytometry to determine differences in CD10 expression in lymphomas and follicular hyperplasias.
METHODS: Cell suspensions from 61 follicular lymphomas, 43 diffuse large B-cell lymphomas, and 44 lymph nodes with follicular hyperplasia were analyzed simultaneously with phycoerythrin-labeled anti-CD20 and fluorescein isothiocyanate-labeled anti-CD10.
RESULTS: CD10 expression was mainly observed on B cells and was detected in 89% of follicular lymphomas, 56% of diffuse large B-cell lymphomas, and 55% of lymph nodes showing follicular hyperplasia. In follicular hyperplasia, two subpopulations of B cells displaying dim and bright CD20 expression were recognized. CD10 expression was restricted to the bright CD20-positive cells, which accounted for an average of 16% of B cells. In CD10-positive follicular and diffuse large B-cell lymphoma cases, a significantly higher proportion of B cells (73%) coexpressed CD10. Furthermore, the intensity of CD10 expression in follicular lymphoma and diffuse large B-cell lymphoma was much higher than that of follicular hyperplasia.
CONCLUSIONS: Quantitative flow cytometry can detect significant differences in CD10 expression between normal follicular cells and follicular or diffuse large B-cell lymphoma. The use of CD10 intensity of expression as well as the fraction of CD10-expressing B cells should help distinguish reactive from neoplastic B-cell processes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625422

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

Review 1.  CD10 expression in diffuse large B-cell lymphomas does not influence survival.

Authors:  Bettina Fabiani; Alain Delmer; Eric Lepage; Catherine Guettier; Tony Petrella; Josette Brière; Anne-Marie Penny; Marie-Christine Copin; Jacques Diebold; Felix Reyes; Philippe Gaulard; Thierry J Molina
Journal:  Virchows Arch       Date:  2004-10-27       Impact factor: 4.064

2.  Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas.

Authors:  I S Lossos; A A Alizadeh; M B Eisen; W C Chan; P O Brown; D Botstein; L M Staudt; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

3.  High frequency of germinal centre derivation in diffuse large B cell lymphoma from Asian patients.

Authors:  A K H Shia; G-G Gan; S Jairaman; S-C Peh
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

4.  Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR).

Authors:  Nicola Mitwasi; Claudia Arndt; Liliana R Loureiro; Alexandra Kegler; Frederick Fasslrinner; Nicole Berndt; Ralf Bergmann; Vaclav Hořejší; Claudia Rössig; Michael Bachmann; Anja Feldmann
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

5.  Normative data for flow cytometry immunophenotyping of benign lymph nodes sampled by surgical biopsy.

Authors:  Gregory David Scott; Susan K Atwater; Dita A Gratzinger
Journal:  J Clin Pathol       Date:  2017-09-15       Impact factor: 3.411

Review 6.  Follicular lymphoid hyperplasia of the posterior maxillary site presenting as uncommon entity: a case report and review of the literature.

Authors:  Masato Watanabe; Ai Enomoto; Yuya Yoneyama; Michihide Kohno; On Hasegawa; Yoko Kawase-Koga; Takafumi Satomi; Daichi Chikazu
Journal:  BMC Oral Health       Date:  2019-11-11       Impact factor: 2.757

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.